Targeted therapy Leveraging ADCC to enhance anti-HER2 therapy

被引:5
|
作者
Killock, David
机构
关键词
D O I
10.1038/nrclinonc.2017.19
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
引用
收藏
页码:200 / 200
页数:1
相关论文
共 50 条
  • [1] Leveraging ADCC to enhance anti-HER2 therapy
    David Killock
    Nature Reviews Clinical Oncology, 2017, 14 : 200 - 200
  • [2] Anti-HER2 immunoliposomes for targeted therapy of human tumors
    Park, JW
    Hong, K
    Kirpotin, DB
    Meyer, O
    Papahadjopoulos, D
    Benz, CC
    CANCER LETTERS, 1997, 118 (02) : 153 - 160
  • [3] Non-HER2 patients may still be targeted for anti-HER2 therapy
    Wilson, Hannah L.
    PERSONALIZED MEDICINE, 2013, 10 (02) : 120 - 121
  • [4] Anti-HER2 Cancer Therapy and Cardiotoxicity
    Babar, Tania
    Blomberg, Christopher
    Hoffner, Eileen
    Yan, Xinhua
    CURRENT PHARMACEUTICAL DESIGN, 2014, 20 (30) : 4911 - 4919
  • [5] Evaluation of cardiotoxicity by anti-HER2 therapy
    Itagaki, Tomoko
    Kajitani, Keiko
    Ohara, Masahiro
    ANNALS OF ONCOLOGY, 2023, 34 : S1433 - S1434
  • [6] Optimal Sequencing of Anti-HER2 Therapy
    Luech, Hans-Joachim
    Untch, Michael
    Jackisch, Christian
    Zielinski, Christoph
    Bartsch, Rupert
    BREAST CARE, 2014, 9 (02) : 138 - 140
  • [7] Fifteen Years of Anti-HER2 Therapy
    Davidson, Nancy E.
    ONCOLOGY-NEW YORK, 2013, 27 (03): : 151 - 151
  • [8] Targeted Radionuclide Therapy with A 177Lu-labeled Anti-HER2 Nanobody
    D'Huyvetter, Matthias
    Vincke, Cecile
    Xavier, Catarina
    Aerts, An
    Impens, Nathalie
    Baatout, Sarah
    De Raeve, Hendrik
    Muyldermans, Serge
    Caveliers, Vicky
    Devoogdt, Nick
    Lahoutte, Tony
    THERANOSTICS, 2014, 4 (07): : 708 - 720
  • [9] Targeted Anti-HER2 Cancer Therapy in Elderly Women Diagnosed with Breast Cancer
    Molina-Garrido, M. J.
    Guillen-Ponce, C.
    Mora-Rufete, A.
    ANTI-CANCER AGENTS IN MEDICINAL CHEMISTRY, 2014, 14 (05) : 639 - 645
  • [10] Anti-HER2 therapy treatment after progression
    von Minckwitz, G.
    EJC SUPPLEMENTS, 2009, 7 (02): : 34 - 35